Jamey Marth, Ph.D.
A holistic and rigorous integration of multiple disciplines is required to perceive and most effectively manipulate the cellular mechanisms of health and disease. The Sanford-Burnham Medical Research Institute facilitates this by supporting the frontiers of biomedical research, the future of interdisciplinary expertise, and the development of more effective therapeutics.
Developing and applying interdisciplinary approaches in cell biology and biomedical research to discover disease origins and mechanisms.
Dr. Marth is Professor and Director of the UC Santa Barbara Center for Nanomedicine, and of the Sanford-Burnham Medical Research Institute.
View All Publications
Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.
Grewal PK, Aziz PV, Uchiyama S, Rubio GR, Lardone RD, Le D, Varki NM, Nizet V, Marth JD
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20218-23
Computational modeling of glucose transport in pancreatic β-cells identifies metabolic thresholds and therapeutic targets in diabetes.
Luni C, Marth JD, Doyle FJ
PLoS One. 2012;7(12):e53130
Pathway to diabetes through attenuation of pancreatic beta cell glycosylation and glucose transport.
Ohtsubo K, Chen MZ, Olefsky JM, Marth JD
Nat Med. 2011 Sep;17(9):1067-75
Mammalian glycosylation in immunity.
Marth JD, Grewal PK
Nat Rev Immunol. 2008 Nov;8(11):874-87
A unified vision of the building blocks of life.
Nat Cell Biol. 2008 Sep;10(9):1015-6
The Ashwell receptor mitigates the lethal coagulopathy of sepsis.
Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V, Marth JD
Nat Med. 2008 Jun;14(6):648-55
Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis.
Green RS, Stone EL, Tenno M, Lehtonen E, Farquhar MG, Marth JD
Immunity. 2007 Aug;27(2):308-20
Conditional mutagenesis of the genome using site-specific DNA recombination.
Ohtsubo K, Marth JD
CSH Protoc. 2007;2007:pdb.top12
Glycosylation in cellular mechanisms of health and disease.
Ohtsubo K, Marth JD
Cell. 2006 Sep 8;126(5):855-67
Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes.
Ohtsubo K, Takamatsu S, Minowa MT, Yoshida A, Takeuchi M, Marth JD
Cell. 2005 Dec 29;123(7):1307-21
A genetic approach to Mammalian glycan function.
Lowe JB, Marth JD
Annu Rev Biochem. 2003;72:643-91
Genetic remodeling of protein glycosylation in vivo induces autoimmune disease.
Chui D, Sellakumar G, Green R, Sutton-Smith M, McQuistan T, Marek K, Morris H, Dell A, Marth J
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1142-7
The ST3Gal-I sialyltransferase controls CD8+ T lymphocyte homeostasis by modulating O-glycan biosynthesis.
Priatel JJ, Chui D, Hiraoka N, Simmons CJ, Richardson KB, Page DM, Fukuda M, Varki NM, Marth JD
Immunity. 2000 Mar;12(3):273-83
The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny.
Shafi R, Iyer SP, Ellies LG, O'Donnell N, Marek KW, Chui D, Hart GW, Marth JD
Proc Natl Acad Sci U S A. 2000 May 23;97(11):5735-9
Core 2 oligosaccharide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and inflammation.
Ellies LG, Tsuboi S, Petryniak B, Lowe JB, Fukuda M, Marth JD
Immunity. 1998 Dec;9(6):881-90
Immune regulation by the ST6Gal sialyltransferase.
Hennet T, Chui D, Paulson JC, Marth JD
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4504-9
Alpha-mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis.
Chui D, Oh-Eda M, Liao YF, Panneerselvam K, Lal A, Marek KW, Freeze HH, Moremen KW, Fukuda MN, Marth JD
Cell. 1997 Jul 11;90(1):157-67
Recent advances in gene mutagenesis by site-directed recombination.
J Clin Invest. 1996 May 1;97(9):1999-2002
T-cell-specific deletion of a polypeptide N-acetylgalactosaminyl-transferase gene by site-directed recombination.
Hennet T, Hagen FK, Tabak LA, Marth JD
Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12070-4
Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting.
Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K
Science. 1994 Jul 1;265(5168):103-6
Complex asparagine-linked oligosaccharides are required for morphogenic events during post-implantation development.
Metzler M, Gertz A, Sarkar M, Schachter H, Schrader JW, Marth JD
EMBO J. 1994 May 1;13(9):2056-65
Will the transgenic mouse serve as a Rosetta Stone to glycoconjugate function?
Glycoconj J. 1994 Feb;11(1):3-8
Tissue- and site-specific DNA recombination in transgenic mice.
Orban PC, Chui D, Marth JD
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6861-5
Jamey Marth's Research Focus
Sepsis, Diabetes - General, Inflammatory/Autoimmune Disease, Coagulopathy, Cancer
Research in the Marth laboratory is centered upon protein glycosylation in the cell biology of disease. The laboratory develops and applies biomedical nanotechnologies in discovering how protein glycosylation participates in the metabolic origins and mechanisms of syndromes including diabetes, autoimmunity, inflammation, cancer, and sepsis. The incorporation of various nanotechnologies into biomedical research is becoming important in the investigation of diseases caused by metabolic and environmental factors that reflect template-independent non-genetic mechanisms. Previous progress by this laboratory included the development of Cre-loxP conditional mutagenesis, a technique that enables cell type-selective and temporally regulated remodeling of the genome in multicellular organisms including mammals. The laboratory applies this technology in the context of transgenesis and gene-targeting to investigate the functions of protein glycosylation and the resulting glycan linkages produced in cells and tissues of living mammals. Glycans are one of the four main families of organic molecules of cells with nucleic acids, proteins, and lipids. Like protein phosphorylation, glycosylation is a metabolic process that alters protein structure and function. This laboratory has found that alterations in protein glycosylation caused by environmental and metabolic stimuli substantially contribute to the origin and severity of diseases and syndromes including obesity-associated diabetes, sepsis, and chronic inflammatory states that develop into more severe disorders including tissue degeneration and autoimmunity. Cancer is another disease wherein significant metabolic signposts include altered glycosylation of proteins. Such highly expressed cell surface tumor antigens that combine glycan and protein sequences in unique combinations may enable more selective drug delivery at high efficiency to further improve upon cancer treatment by nanomedicine. The laboratory includes interdisciplinary research in collaborations with bioengineers and clinicians to develop improved diagnostic and therapeutic strategies that can detect and intervene in the early cellular dysfunction of disease. These discoveries provide a rationale for therapeutic development efforts that leverages our understanding of metabolic components and environmental factors to more effectively intervene in the onset and progression of disease.
About Jamey Marth
Jamey Marth is Professor and Director of the University of California Santa Barbara Center for Nanomedicine, and of the Sanford-Burnham Medical Research Institute. He is also a Professor in the UCSB Department of Molecular, Cellular and Developmental Biology, and in the UCSB Biomolecular Science and Engineering program. Dr. Marth is the inaugural recipient of the UCSB Carbon Endowed Chair of Biochemistry and Molecular Biology and a recipient of the UCSB Mellichamp Endowed Chair of Systems Biology. Dr. Marth received a Ph.D. degree in Pharmacology from the University of Washington where he trained in the laboratories of Roger M. Perlmutter, current Executive Vice-President of Merck, and the late Edwin G. Krebs, a 1992 Nobel Prize laureate. Dr. Marth was recruited to UC San Diego in 1995 by George Palade - a 1974 Nobel Prize laureate, where he was appointed as an Investigator of the Howard Hughes Medical Institute and Professor in the Department of Cellular and Molecular Medicine, prior to his current positions.
Ph.D., University of Washington, Pharmacology, 1987
B.S., University of Oregon, Genetics and Chemistry, 1984
Director, UCSB Center for Nanomedicine
Professor, UCSB Department of Molecular, Cellular and Developmental Biology
Professor UCSB Biomolecular Sciences and Engineering
Funding Awards and Collaborative Grants
Howard Hughes Medical Institute Investigator award, 1995-2009
Hearst Foundations, 2011-2013
Honors and Recognition
John Carbon Chair in Biochemistry and Molecular Biology, 2009 - Pres.
Duncan and Suzanne Mellichamp Chair in Systems Biology, 2009 - Pres.
Investigator, Howard Hughes Medical Institute, 1995 - 2009
University of California San Diego, Professor, 1999 - 2009
Faculty Scholarship, The Medical Research Council of Canada, 1991 - 1995